EDITORIAL COMMENT

Continuous Direct Left Atrial Pressure During MitraClip Therapy
One Key to Clinical Success?*

Patrice Guérin, MD, PhD

Mitral regurgitation (MR) is frequent, being the second most common form of valvular heart disease. It is classified as either primary (degenerative) or secondary (functional). Although surgery (surgical repair or replacement) is indicated for severe primary MR, about 50% of patients are considered too high risk to be suitable for surgery because of their age and/or comorbidities (1,2). This has paved the way for the development of catheter-based interventions to correct MR percutaneously. The MitraClip system (Abbott Vascular, Menlo Park, California) is the only technique that has been evaluated for transcatheter organic MR repair so far, providing a therapeutic alternative to open heart surgery. Although less effective in reducing the degree of MR, the MitraClip was proved to be safer than surgery in EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) (3,4).

Because residual MR after MitraClip placement is associated with suboptimal outcomes and increases mortality, the goal of the procedure is to reduce MR as much as possible, so that implantation of multiple clips is often needed (3). Nevertheless, multiple clip implantation is associated with a reduction of the mitral valve opening area and an increase in the transmitral pressure gradient. Hence, the goal is to define an acceptable compromise between residual MR and transmitral gradient. Indeed, it has been demonstrated that both mitral stenosis and MR after MitraClip therapy have a negative impact on the long-term clinical outcomes of treated patients (5,6). Transesophageal echocardiography and color Doppler are the only tools to assess both residual MR and transmitral gradient, but accurate echocardiographic evaluations are limited by operator dependence and the fact that the analysis of a double-orifice valve is challenging (7,8). Indeed, the native mitral orifice is reduced and divided into 2 or more separate orifices with often eccentric residual jets (9–11). Hemodynamic parameters could be helpful to guide MC therapy. Intraprocedural assessment of left atrial pressure (LAP) has been described as a helpful tool during MitraClip implantation (12,13). Eled et al. (12) described a simplified technique to assess continuous and real-time LAP during MitraClip therapy. Horstkotte et al. (13) showed that multimodality assessment of intraprocedural MR (including transesophageal echocardiographic evaluation and LAP monitoring) was associated with superior intraprocedural results leading to improved MR reduction.

In this issue of JACC: Cardiovascular Interventions, Kuwata et al. (14) report their prospective use of continuous real-time direct measurements of LAP and left ventricular pressure during MitraClip therapy. They assessed the additional benefit of measuring left-sided heart pressures as a complement to echocardiographic assessment during MitraClip therapy and assessed the prognostic impact of left atrial hemodynamic status on clinical outcomes at short-term follow-up. A minority (30%) of included patients had secondary MR. The most important study finding was the existence of a relation between indexed mean LAP (LAP adjusted to left ventricular pressure) and clinical outcomes: post-implantation increase of indexed mean LAP was significantly associated with heart failure and rehospitalization at follow-up, independently of echocardiographic findings (p = 0.044). This study is the first to provide

*Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.

From the University Hospital of Nantes, l’Institut du Thorax, Interventional Cardiology Unit, Nantes, France. Dr. Guérin has received research, proctoring, and speaker fees from Abbott Vascular; speaker fees from General Electric; and research fees from Boston Scientific, Medtronic, and Biotronik.

ISSN 1936-8798/$36.00

First, it would be very interesting to evaluate continuous pressure and cardiac output during MitraClip therapy. It has been shown that the reduction in regurgitant volume results in acute augmentations in forward cardiac output and forward stroke volume (15).

Second, specific studies on primary versus secondary MR are needed, because population and diseases are not the same. In the recently published MitraFr study, there was no evident benefit of MitraClip therapy in case of functional MR with a left ventricular ejection fraction lower than 40% (16). It is questionable whether this study could have given different results with per procedure LAP monitoring.

Third, because it has been proved that left atrial v-wave pressure measurement through a dedicated catheter during MitraClip therapy has superior accuracy compared with the manufacturer-provided steerable guiding catheter, and because parallel puncture of the femoral vein could be responsible for hemorrhagic complication, we await a dedicated steerable guiding catheter allowing direct and continuous LAP and cardiac output monitoring (17).

**REFERENCES**

14. Kuwata ST, Czopak M, Luciani A, et al. Continuous direct left atrial pressure...

**ADDRESS FOR CORRESPONDENCE:** Dr. Patrice Guérin, CHU Nantes, l’Institut du Thorax, Unité d’Héodynamique, Hôpital Guillaume et René Laennec, Boulevard Jacques Monod, 44035 Nantes cedex 01, France. E-mail: patrice.guerin@chu-nantes.fr.


KEY WORDS edge-to-edge repair, guiding, left atrial pressure, MitraClip